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Abstract
Background—Medications development efforts for methamphetamine-use disorder have 
targeted central monoamines because these systems are directly involved in the effects of 
methamphetamine. Buspirone is a dopamine autoreceptor and D3 receptor antagonist and partial 
agonist at serotonin 1A receptors, making it a logical candidate medication for methamphetamine-
use disorder. Buspirone effects on abuse-related behaviors of methamphetamine have been mixed 
in clinical and preclinical studies. Experimental research using maintenance dosing, which models 
therapeutic use, is limited. This study evaluated the influence of buspirone maintenance on the 
reinforcing effects of methamphetamine using a self-administration procedure, which has 
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predictive validity for clinical efficacy. The impact of buspirone maintenance on the subjective and 
cardiovascular response to methamphetamine was also determined.
Methods—Eight research participants (1 female) reporting recent illicit stimulant use completed 
a placebo-controlled, crossover, double-blind protocol in which the pharmacodynamic effects of 
intranasal methamphetamine (0, 15, and 30 mg) were assessed after at least 6 days of buspirone (0 
and 45 mg/day) maintenance.
Results—Intranasal methamphetamine functioned as a reinforcer and produced prototypical 
stimulant-like subjective (e.g., increased ratings of Good Effects and Like Drug) and 
cardiovascular (e.g., elevated blood pressure) effects. These effects of methamphetamine were 
similar under buspirone and placebo maintenance conditions. Maintenance on buspirone was well 
tolerated and devoid of effects when administered alone.
Conclusions—These data suggest that buspirone is unlikely to be an effective pharmacotherapy 
for methamphetamine-use disorder. Given the central role of monoamines in methamphetamine-
use disorder, it is reasonable for future studies to continue to target these systems.
Keywords
methamphetamine; buspirone; maintenance; subjective effects; cardiovascular effects
1. Introduction
Methamphetamine-use disorder is a significant public health problem. Nearly 1 million 
Americans over the age of 12 report past month methamphetamine use (Center for 
Behavioral Health Statistics and Quality, 2016). One-tenth of substance abuse treatment 
admissions reported amphetamines as their primary substance of abuse (Substance Abuse 
and Mental Health Services Administration, 2015). The cost (e.g., premature death, crime, 
and decreased productivity) of methamphetamine-use disorder is estimated at $23 billion 
annually (Nicosia et al., 2009; Pasic et al., 2007; Shoptaw et al., 2009). Behavioral therapies 
(e.g., contingency management) modestly reduce methamphetamine use (e.g., Landovitz et 
al., 2015; Shoptaw et al., 2006; Smout et al., 2010). However, most patients are unable to 
sustain abstinence, suggesting novel treatment strategies such as pharmacotherapy are 
needed.
Medications development has targeted central monoamine systems (e.g., dopamine, 
serotonin, and norepinephrine) (e.g., Anderson et al., 2015; Brensilver et al., 2013; Rush et 
al., 2011) because these systems are directly involved in the effects of methamphetamine 
(Fleckenstein et al., 2000, 2007; Rothman and Glowa, 1995). Buspirone is a non-
benzodiazepine anxiolytic that functions as a dopamine autoreceptor and D3 receptor 
antagonist and partial serotonin 1A agonist (e.g., Heidbreder, 2008; Mahmood and 
Sahajwalla, 1999; Volkow and Skolnick, 2012). Prior studies examining the influence of 
acute buspirone treatment on the abuse-related behavioral effects of amphetamines have 
yielded mixed results. In rats, buspirone attenuated the locomotor effects of 
methamphetamine (Jackson et al., 1994) and cue-induced reinstatement (Shelton et al., 
2013), but not the discriminative-stimulus effects (Munzar et al., 1999). In rhesus monkeys, 
buspirone attenuated the discriminative-stimulus effects of methamphetamine (Nader and 
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Woolverton, 1994) but not methamphetamine self-administration (John et al., 2015). In the 
human laboratory, buspirone pretreatment enhanced some subjective effects of oral 
methamphetamine (e.g., Good Effects and Like Drug), but attenuated the cardiovascular 
effects (Pike et al., 2016). Those studies employed acute buspirone dosing, which does not 
reflect how buspirone would be used in the clinic. One pilot human laboratory study showed 
that buspirone maintenance is safe when combined with intravenous methamphetamine 
(Paterson et al., 2014), but a notable limitation of that study is the lack of a placebo control.
The purpose of this placebo-controlled human laboratory study was, therefore, to determine 
the initial efficacy, safety, and tolerability of buspirone maintenance for methamphetamine-
use disorder. The primary outcome was drug self-administration given the predictive validity 
of self-administration procedures for clinical efficacy (Comer et al., 2008; Czoty et al., 2016; 
Haney and Spealman, 2008). The influence of buspirone on the subjective and 
cardiovascular effects of methamphetamine was also assessed.
2. Materials and Methods
2.1. Participants
Eight (N = 1 female, 7 male) non-treatment seeking adult participants who were currently 
using an illicit stimulant completed this within-subjects, placebo-controlled study. The 
Institutional Review Board of the University of Kentucky (UK) Medical Center approved all 
procedures. Participants gave their written informed consent prior to study participation. 
Participants were compensated for their participation.
Participants underwent a comprehensive physical and mental health screening process (see 
Sevak et al., 2011). Participants were required to report recent illicit stimulant use confirmed 
by a positive urine screen and fulfill diagnostic criteria for stimulant abuse or dependence on 
a computerized version of the Structured Clinical Interview for the Diagnostic and Statistical 
Manual of Mental Disorders-IV (SCID). Potential participants were excluded if they had 
current or past histories of serious physical disease or psychiatric disorders, or reported 
physical withdrawal symptoms.
Participants ranged in age from 30–50 years (mean 41 years) and in weight from 55–104 kg 
(mean 85 kg). Three were African-American, 3 were Caucasian, 1 was Caucasian Hispanic/
Latino, and 1 was African-American/Caucasian. Seven reported smoking tobacco cigarettes 
(range: 5–20 cigarettes/day; mean: 13 cigarettes/day). All participants reported lifetime 
illicit amphetamine use and past month cocaine use. One also reported past month 
amphetamine use. Participants reported recreational use of a range of substances (e.g., 
alcohol, caffeine, and marijuana).
2.2. Study Procedures
Participants were enrolled as inpatients at the UK Chandler Medical Center Clinical 
Services Core (CSC) for at least 22 days and completed 1 drug-free practice session and 6 
experimental sessions.
Reynolds et al. Page 3
Drug Alcohol Depend. Author manuscript; available in PMC 2018 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2.2.2. Drug Maintenance and Administration—Drug maintenance began on the day 
after the practice session and continued throughout the protocol. The order of drug 
maintenance conditions was counter-balanced. Drugs were administered in a double-blind 
fashion. Placebo and buspirone (target dose = 45 mg/day) were administered orally at 0700, 
1500, and 2300 hours. After completing the first maintenance period, participants were 
crossed over to the other maintenance condition (Figure 1). Buspirone was titrated (i.e., 5 
mg three times daily for 1 day, 10 mg three times daily for 2 days, and 15 mg three times 
daily for the remainder of the maintenance period) up to the target dose. Doses were 
prepared by over-encapsulating commercially buspirone HCl tablets (5, 10, or 15 mg) in size 
0 capsules. Placebo capsules contained cornstarch only.
Methamphetamine doses (0, 10, and 30 mg) were prepared by combining methamphetamine 
hydrochloride (National Institute on Drug Abuse, Research Triangle Park, NC) with lactose 
to equal 50 mg powder. During methamphetamine administration, a nurse provided 
participants with the powder, a mirror, and a razor blade. They were instructed to divide the 
powder into 2 “equal” lines and insufflate one line of powder through each nostril using a 
65-mm plastic straw within 2 minutes.
2.2.3. Experimental Sessions—Experimental sessions started at 0900 and lasted 8 
hours. Urine and expired air breath samples were collected prior to each experimental 
session to confirm drug and alcohol abstinence, respectively. Participants occasionally tested 
positive for amphetamine, which coincided with experimental administration. In the 
morning, participants sampled the intranasal methamphetamine dose (0, 10, and 30 mg; 
administered in random order) available later in session. In the afternoon, participants 
completed the modified-progressive ratio procedure and the portion of the dose earned on 
the task was administered an hour later. Subjective and cardiovascular effects were recorded 
prior to and at 15-minute intervals for 120 minutes following drug administration.
2.3. Outcome Variables
2.3.1. Drug Self-Administration—Participants had 10 opportunities to work to earn a 
portion of the drug sampled that morning (0, 10, or 30 mg intranasal methamphetamine). 
Participants completed a computerized modified progressive-ratio task by clicking the 
computer mouse to earn a portion of the total available dose. Participants were instructed 
that they could earn all or a portion of the sampled dose. Each completed ratio earned 1/10th 
of the sampled dose. To complete the first ratio, participants were required to click 400 
times. Each additional ratio increased by 100. Participants could terminate the task at any 
time by clicking a button labeled stop. The primary outcome variable was number of ratios 
completed.
2.3.2. Subjective Effect Questionnaires—Two subjective effect questionnaires were 
administered in a fixed order: 1) the Adjective Rating Scale (Oliveto et al., 1992) and 2) a 
Visual Analog Scale Drug Effect Questionnaire (Rush et al., 2003).
2.3.3. Cardiovascular Effects—Heart rate, blood pressure, temperature, and 
electrocardiography were recorded at regular intervals using an automated monitor. 
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Sampling or self-administered doses were withheld if systolic and diastolic blood pressures 
were at or above 150 mmHg, 100 mmHg respectively, or if heart rate was at or above 100 
bpm. None of the doses were withheld for exceeding these parameters.
2.4. Data Analysis
Effects with p < .05 were considered significant. Modified progressive-ratio data (i.e., 
number of drug choices) were analyzed with two-factor, repeated measure analysis of 
variance (ANOVA; IBM SPSS Statistics version 24, IBM Corporation, Armonk, NY) with 
methamphetamine (0, 10, and 30 mg) and buspirone (0 and 45 mg) as factors. Fisher’s Least 
Significant Difference (LSD) post hoc tests were used to interpret significant ANOVA 
outcomes for significant main effects or interactions. Comparisons were between active 
conditions and placebo (i.e., 0 mg methamphetamine and 0 mg buspirone). Subjective 
effects and cardiovascular data from sampling sessions were analyzed similarly as peak 
effect.
3. Results
3.1. Drug Reinforcement
A main effect of methamphetamine only was found for number of drug choices (F2,14 = 
12.42, p = .001) on the modified progressive-ratio procedure. Active methamphetamine 
doses increased the number of drug choices relative to placebo regardless of maintenance 
condition (Figure 2).
3.2. Subjective Effects Questionnaires
3.2.1. Adjective Rating Scale—A main effect of methamphetamine only was detected 
for scores on the Stimulant subscale of the Adjective Rating Scale (F2,14 = 20.59, p < .001; 
data not shown). Active methamphetamine doses significantly increased these scores relative 
to placebo regardless of maintenance condition.
3.2.2. Drug Effect Questionnaire—A main effect of methamphetamine only was 
observed on 10 items from the Drug Effect Questionnaire: Active-Alert-Energetic, Any 
Effect, Good Effects, High, Like Drug, Willing to Pay For, Rush, Stimulated, Willing to 
Take Again, and Talkative (F2,14 values > 5.98, p values < .013; representative data are 
depicted in Figure 2). Across maintenance conditions, active methamphetamine doses 
generally increased ratings on these items relative to placebo with the exception that 10 mg 
methamphetamine did not significantly increase ratings of Active-Alert-Energetic, Willing 
to Pay For, and Talkative.
3.3. Cardiovascular Effects
A main effect of methamphetamine only was found for systolic and diastolic blood pressure 
(F2,14 values > 3.86, p values < .05). Figure 2 shows that 30 mg methamphetamine produced 
significant increases in systolic blood pressure relative to placebo.
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4. Discussion
This study demonstrated that methamphetamine functioned as a reinforcer, with near 
maximal responding observed for the highest dose tested. Methamphetamine also produced 
a constellation of prototypical stimulant-like subjective effects indicative of abuse potential 
(e.g., Good Effects and Like Drug) and elevated systolic and diastolic blood pressure. These 
effects are consistent with the type and magnitude of effects typically observed following 
methamphetamine administration by various routes (e.g., Hart et al., 2001; Kirkpatrick et al., 
2012; Marks et al., 2016; Pike et al., 2016; Stoops et al., 2015), but was not impacted by 
buspirone maintenance.
These findings are concordant with preclinical studies showing that buspirone failed to 
attenuate methamphetamine choice (John et al., 2015) and methamphetamine discrimination 
in rats (Munzar et al., 1999). By contrast, buspirone attenuated locomotor effects (Jackson et 
al., 1994), cue-induced reinstatement (Shelton et al., 2013), and the discriminative-stimulus 
effects (Nader and Woolverton, 1994) of methamphetamine in other preclinical studies. In 
the human laboratory, acute buspirone administration enhanced some of the subjective 
effects of low doses of oral methamphetamine (e.g., Good Effects and Like Drug) (Pike et 
al., 2016). Mixed results have also been observed in behavioral studies that examined 
interactions between buspirone and cocaine (Bergman et al., 2013; Czoty and Nader, 2015; 
Gold and Balster, 1992; John et al., 2015, Mello et al., 2013). The reasons for these 
discrepancies are unknown, but could reflect differences between acute and maintenance 
dosing of dopamine antagonists on effects of psychomotor stimulants (Haney and Spealman, 
2008) or route of psychomotor stimulant administration (e.g., intranasal, oral, or 
intravenous).
This study also assessed the safety and tolerability of buspirone maintenance, alone and in 
combination with methamphetamine. Buspirone was devoid of effects when administered 
alone. No subjects withdrew from the study due to study medications and no serious adverse 
events occurred. These data are consistent with prior reports showing that the combination 
of buspirone with methamphetamine (Pike et al., 2016; Paterson et al., 2014) and cocaine 
(Bolin et al., 2016) is safe and tolerable. These findings are also concordant with a past 
study demonstrating that buspirone alone does not engender subjective effects (Strickland et 
al., 2017).
A limitation of the present study is that a small sample size was enrolled. However, the 
reinforcing, subjective, and cardiovascular effects of methamphetamine were detected with 
medium to large effect sizes (i.e., ranging from .36 – .85) (Olejnik and Algina, 2000). 
Second, although self-administration outcomes are thought to best predict 
pharmacotheraputic efficacy compared to other laboratory-based screening procedures 
(Comer et al., 2008; Haney and Spealman, 2008), whether buspirone would alter other 
aspects of addiction (e.g., vulnerability to relapse) (Koob and Le Moal, 2001) is unknown. 
Considering the negative results with buspirone on cocaine use in the natural ecology 
(Moeller et al., 2001; Winhusen et al., 2014) and the present findings, buspirone would 
likely have limited efficacy for methamphetamine-use disorder.
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Highlights
• The pharmacodynamic effects of methamphetamine during buspirone 
maintenance were determined.
• Methamphetamine functioned as a reinforcer and produced prototypic 
subjective effects.
• Buspirone and methamphetamine combinations were safe and tolerable.
• Buspirone maintenance did not change methamphetamine self-administration.
• Buspirone maintenance did not change methamphetamine subjective effects.
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Figure 1. 
Experiment timeline. The order of methamphetamine sampling doses was randomized and 
the order of buspirone maintenance was counter-balanced across participants. Boxed 
numbers (i.e., 1–6) on the top row denote experimental sessions. Numbers on the bottom 
row (i.e., 1–22) denote calendar days.
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Figure 2. 
The top left panel illustrates the number of ratios completed for methamphetamine (top left 
panel) during buspirone maintenance. The remaining panels demonstrate the peak effects of 
the sampling doses of methamphetamine during buspirone maintenance on systolic blood 
pressure (top right panel), and subject ratings of Active-Alert-Energetic (middle left panel), 
Good Effects (middle right panel), Like Drug (bottom left panel), and Willing to Take Again 
(bottom right panel). The X-axis represents methamphetamine dose. For all panels, circles 
represent 0 mg buspirone and squares represent 45 mg buspirone. Filled symbols indicate a 
significant difference from placebo using Fisher’s LSD post hoc test. Error bars represent 
standard error of the mean. N = 8 for all data points.
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